Sfoglia per Autore
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders
2011 S. Piconi, S. Parisotto, G. Rizzardini, S. Passerini, R. Terzi, B. Argenteri, P. Meraviglia, A. Capetti, M. Biasin, D. Trabattoni, M. Clerici
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
2013 S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Focà, A. Capetti, P. Meraviglia, C. Abeli, S. Bonora, M. D'Annunzio, A. Di Biagio, M. Di Pietro, L. Butini, G. Orofino, M. Colafigli, G. D'Ettorre, D. Francisci, G. Parruti, A. Soria, A.R. Buonomini, C. Tommasi, S. Mosti, F. Bai, S. Di Nardo Stuppino, M. Morosi, M. Montano, P. Tau, E. Merlini, G. Marchetti
OPERA : use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients
2014 G. Carosi, R. Bruno, G. Cariti, P. Nasta, R. Gulminetti, M. Galli, G. Angarano, G. Verucchi, E. Pontali, A. Capetti, E. Raise, V. Ravasio, I. Maida, C. Iannacone, A. Caputo, M. Puoti
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies : evidence from Phase I studies in healthy volunteers
2014 M.V. Cossu, D. Cattaneo, S. Fucile, P. Pellegrino, S. Baldelli, V. Cozzi, A. Capetti, E. Clementi
OPERA : responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy
2015 R. Bruno, G. Cariti, P. Nasta, A. Capetti, V. Ravasio, M. Galli, E. Raise, G. Palmieri, C. Iannacone, M. Puoti
Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers : a randomized, open-label, 2-period, single-dose, crossover phase 1 study
2015 D. Cattaneo, M.V. Cossu, S. Fucile, A. Riva, S. Baldelli, P. Meraviglia, S. Landonio, C. Impagnatiello, C. Resnati, M. Galli, E. Clementi, A. Capetti, G. Rizzardini, C. Gervasoni
Antiretroviral therapy through barriers : a prominent role for nanotechnology in HIV-1 eradication from sanctuaries
2016 F. Corsi, L. Sorrentino, S. Mazzucchelli, M. Truffi, A. Capetti, G. Rizzardini, L. Fiandra
Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects : an Italian cohort
2016 A.F. Capetti, G. Sterrantino, M.V. Cossu, G. Cenderello, A.M. Cattelan, G.V. De Socio, S. Rusconi, N. Riccardi, G.M. Baldin, S. Cima, F.P. Niero, G. Rizzardini, L. Sasset
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides
2016 A. Di Biagio, N. Riccardi, L. Taramasso, A. Capetti, G. Cenderello, A. Signori, P. Vitiello, M. Guerra, G.V. de Socio, G. Cassola, T. Quirino, C. Viscoli
Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art
2017 L. Fiandra, A. Capetti, L. Sorrentino, F. Corsi
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients
2017 A. Borghetti, G. Baldin, A. Capetti, G. Sterrantino, S. Rusconi, A. Latini, A. Giacometti, G. Madeddu, C. Picarelli, R. De Marco, M.V. Cossu, F. Lagi, R. Cauda, A. De Luca, S. Di Giambenedetto
Effects of ritonavir and cobicistat on dolutegravir exposure : when the booster can make the difference
2017 C. Gervasoni, A. Riva, V. Cozzi, A.F. Capetti, G. Rizzardini, E.G.I. Clementi, D. Cattaneo
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016
2018 B. Rossetti, S. Di Giambenedetto, C. Torti, M.C. Postorino, G. Punzi, F. Saladini, W. Gennari, V. Borghi, L. Monno, A.R. Pignataro, E. Polilli, M. Colafigli, A. Poggi, S. Tini, M. Zazzi, A. De Luca, V. Mellace, A. Capetti, M.R. Gismondo, M.L. Biondi, C. Mussini, M. Pecorari, N. Gianotti, D. Sacchini, G. Parruti, F. Baldelli, S. Zanussi, A. Nerli, L. Lenzi, C. Calzetti, A. Vivarelli, R. Maserati, F. Baldanti, F. Poletti, V. Mondino, M. Malena, A. Cascio, G. Filice, G. Magnani, A. Zerbini, F. Lombardi, S. Di Gaimbenedetto, M. Andreoni, M. Montano, V. Vullo, O. Turriziani, A. Gonnelli, E. Boeri, S. Bonora, V. Ghisetti, D. Francisci, P. Grossi, P. Bagnarelli, L. Butini, R. del Gobbo, A. Giacometti, D. Tacconi, A. Callegaro, F. Maggiolo, A. Zoncada, E. Paolini, L. Sighinolfi, G. Colao, P. Corsi, P. Blanc, L. Galli, P. Meraviglia, A. Tosti, B. Bruzzone, M. Setti, G. Penco, A. Di Biagio, C. Nencioni, R. Pardelli, I. Arcidiacono, A. Degiuli, M. De Gennaro, A. Soria, A. Foc, S. Latella, L. Cosco, S. Malandrin, P. Milini, P. Cicconi, S. Rusconi, V. Micheli
Dolutegravir plus rilpivirine as a switch option in cART-experienced patients : 96-week data
2018 A.F. Capetti, M.V. Cossu, G. Sterrantino, G. Barbarini, S. Di Giambenedetto, G.V. De Socio, G. Orofino, A. Di Biagio, B.M. Celesia, S. Rusconi, B. Argenteri, G. Rizzardini
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients
2018 A. Ciccullo, G. Baldin, A. Capetti, S. Rusconi, G. Sterrantino, G. D'Ettorre, M. Colafigli, S. Modica, F. Lagi, A. Giacomelli, M.V. Cossu, S. Restelli, A. De Luca, S. Di Giambenedetto
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study
2019 G. Baldin, A. Ciccullo, A. Capetti, S. Rusconi, G. Sterrantino, M. Cossu, A. Giacomelli, F. Lagi, A. Latini, P. Bagella, A. De Luca, S. Di Giambenedetto, G. Madeddu
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents
2019 V. Giacomet, M.V. Cossu, A.F. Capetti, G.V. Zuccotti, G. Rizzardini
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients
2019 G. Baldin, A. Ciccullo, S. Rusconi, A. Capetti, G. Sterrantino, M. Colafigli, G. D'Ettorre, A. Giacometti, M.V. Cossu, A. Borghetti, W. Gennari, C. Mussini, V. Borghi, S. Di Giambenedetto
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study
2019 G. Baldin, A. Ciccullo, S. Rusconi, G. Madeddu, G. Sterrantino, A. Freedman, A. Giacometti, L. Celani, A. Latini, B. Rossetti, M.V. Cossu, A. Giacomelli, F. Lagi, A. Capetti, S. Di Giambenedetto
Cohort profile : The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
2019 A. Ciccullo, G. Baldin, A. Capetti, V. Borghi, G. Sterrantino, A. Latini, G. Madeddu, L. Celani, F. Vignale, B. Rossetti, A. Dusina, M.V. Cossu, S. Restelli, W. Gennari, F. Lagi, A. Giacomelli, M. Colafigli, L. Brescini, A. Borghetti, C. Mussini, S. Rusconi, S. Di Giambenedetto
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile